A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry

Molecular Pharmacology

Volumn 57, Issue 1, 2000, Pages 116-124

  Daelemans, Dirk ^a   Schols, Dominique ^a   Witvrouw, Myriam ^a   Pannecouque, Christophe ^a   Hatse, Sigrid ^a   Van Dooren, Sonia ^a   Hamy, François ^b   Klimkait, Thomas ^b,c   De Clercq, Erik ^a   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CALCIUM; CHEMOKINES, CXC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; GENES, TAT; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HIV-2; HUMANS; LEUKOCYTES, MONONUCLEAR; OLIGOPEPTIDES; PEPTOIDS; RECEPTORS, CXCR4; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 0033971512     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM and Berger EA (1996) CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (Wash DC) 272:1955-1958.
2. Arya SK, Guo C, Josephs SF and Wong-Staal F (1985) Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science (Wash DC) 229:69-73.
3. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J and De Clercq E (1988) Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 85:6132-6136.
4. Balzarini J, Pérez-Pérez M-J, San-Felix A, Schols D, Perno C-F, VanDamme A-M, Camarasa M-J and De Clercq E (1992) 2′5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA 89:4392-4396.
5. Berger J, Hauber J, Hauber R, Geiger R and Cullen B (1988) Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. J Virol 68:1179-1185.
6. Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, David G, De Clercq E and Debyser Z (1997) Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol 52:771-780.
7. Cullen BR (1998) HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 93:685-692.
8. Daelemans D, Esté JA, Witvrouw M, Pannecouque C, Jonckheere H, Aquaro S, Perno C-F, De Clercq E and VanDamme A-M (1997) S-Adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. Mol Pharmacol 52: 1157-1163.
9. Daeleraans D, VanDamme A-M and De Clercq E (1999) Human immunodeficiency virus (HIV) gene regulation inhibitors as target for antiviral therapy. Antiviral Chem Chemother 10:1-14.
10. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M and Picker D (1992) Potent and selective inhibition of human immunodeficiency virus HIV-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 89:5286-5290.
11. De Vreese K, Reymen D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, Esté JA, James W, Henson G, Desmyter J, Anné J and De Clercq E (1996) The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res 29:209-219.
12. Deng H, Unutmaz D, KewalRamani VN and Littman DR (1997) Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (Lond) 388:296-300.
13. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E and Moore JP (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77.
14. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW and O'Brien WA (1997) A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as and HIV-1 coreceptor. J Exp Med 186:1395-1400.
15. Dreyer GB, Metcalf BW, Tomaszek TA, Carr TJ, Chandler AC, Hyland L, Fakhoury SA, Magaard VW, Moore ML, JE Strickler, Debouck C and TD Meek (1989) Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc Natl Acad Sci USA 86:9752-9756.
16. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, Thomas JF, Stoebenau-Haggarty B, Choe S, Vance PJ, Wells TNC, Power CA, Sutterwala SS, Doms RW, Landau NR and JA Hoxie (1996) CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87:745-756.
17. Esté JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J and De Clercq E (1998) Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 53:340-345.
18. Felber BK, Drysdale CM and Pavlakis GN (1990) Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein. J Virol 64:3734-3741.
19. Förster R, Kremmer E, Schubel A, Breitfeld D, Kleinschmidt A, Nerl C, Bernhardt G and Lipp M (1998) Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: Rapid internalization and recycling upon activation. J Immunol 160:1522-1531.
20. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-Ela F, Varani G, Karn J and Klimkait T (1997) An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 94:3548-3553.
21. Hsu M-C, Schutt D, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ and Volsky DJ (1991) Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist. Science (Wash DC) 254:1799-1802.
22. Huang P, Farquhar D and Plunkett W (1990) Selective action of 3′-azido-3′-deoxythimidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 265:11914-11918.
23. Labrosse B, Brelot A, Heveker H, Sol N, Schols D, De Clercq E and Alizon M (1998) Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381-6388.
24. Larder BA and Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (Wash DC) 246:1155-1158.
25. Laspia MF, Rice AP and Mathews MB (1989) HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283-292.
26. Maio JJ and Brown FL (1988) Regulation of expression driven by human immunodeficiency virus type 1 and human T-cell leukemia virus type E long terminal repeats in pluripotential human embryonic cells. J Virol 62:1398-1407.
27. + cells. Science (Wash DC) 240:646-649.
28. Murakami T, Nakajima T, Koyanagi N, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N and Nagasawa T (1997) A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389-1393.
29. Neumann M, Harrison J, Saltarelli M, Hadziyannis E, Erfle V, Felber BK and Pavlakis GN (1994) Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. AIDS Res Hum Retroviruses 10:1531-1542.
30. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M and Moser B (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (Lond) 382:833-835.
31. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J and De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309-321.
32. Popovic M, Sarngadharan MG, Read E and Gallo RC (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (Wash DC) 224:497-500.
33. Schols D, Esté JA, Cabrera C and De Clercq E (1998) T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 72:4032-4037.
34. Schols D, Esté JA, Henson G and De Clercq E (1997a) Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 35:147-156.
35. Schols D, Struyf S, Van Damme J, Esté JA, Henson G and De Clercq E (1997b) Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388.
36. Sodroski J, Rosen C, Wong SF, Salahuddin SZ, Popovic M, Arya SK, Gallo RC and Haseltine WA (1985) Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science (Wash DC) 227:171-173.
37. Spire B, Sire J, Zachar V, Rey F, Barré-Sinoussi F, Galibert F, Hampe A and Chermann JC (1989) Nucleotide sequence of HIV-1-NDK: A highly cytopathic strain of human immunodeficiency virus. Gene 81:275-284.
38. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ and Martin MA (1988) In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62:139-147.
39. Witvrouw M, Pauwels R, VanDamme A-M, Schols D, Reymen D, Yamamoto N, Desmyter J and De Clercq E (1992) Cell-type specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob Agents Chemother 36:2628-2633.